Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Inclusion Criteria: * Histologically confirmed biliary tract or gallbladder cancer that have relapsed or are refractory after one prior gemcitabine-based chemotherapy regimen for advanced biliary cancer * Evaluable disease * ECOG PS ≤ 2 * Adequate bone marrow, liver and renal function Exclusion Criteria: * Treatment with more than one prior chemotherapy regimen * Known, uncontrolled CNS metastases * Baseline peripheral neuropathy ≥ grade 2. * Significant circulatory disorders in the past 6 months * Concomitant use of phosphodiesterase inhibitors